
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is a clinical-stage biopharmaceutical company that has recently reported its Q2 FY26 results, showing a lower-than-expected revenue of $0.1 million and an EPS of $(0.16). Despite this, they have received marketing authorization for their ophthalmic formulation of ONS-5010/LYTENAVA and have significant upside potential as they are expecting FDA approval within the next 60 days for their main therapeutic candidate. Additionally, their LYTENAVA product has potential pricing and reimbursement advantages, making it a strong competitor in the market.
Bears say
Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, for various ophthalmic indications. While the company recently received marketing authorization for ONS-5010/LYTENAVA in the EU and UK, with plans for additional launches in other European countries, there are significant risks involved, including balance sheet and liquidity risks, potential competition, and the need for product candidates to demonstrate safety and efficacy in clinical trials. While there is potential for significant growth and upside opportunities, these risks warrant a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares